The role of cytokines in inflammatory bone loss

Immunological Investigations

Volumn 42, Issue 7, 2013, Pages 555-622

  Souza, Pedro P C ^a   Lerner, Ulf H ^b,c  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bone loss; Cytokines; Inflammation; Osteoclasts

Indexed keywords

CARDIOTROPHIN 1; CD11B ANTIGEN; COLONY STIMULATING FACTOR 1; CYTOKINE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 20; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 32; INTERLEUKIN 33; INTERLEUKIN 34; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN M; OSTEOCLAST DIFFERENTIATION FACTOR; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALVEOLAR BONE; ARTICLE; BONE REMODELING; CELL DIFFERENTIATION; CYTOKINE RESPONSE; FIBROBLAST; HUMAN; IMMUNOSTIMULATION; INFLAMMATORY DISEASE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OSTEOSCLEROSIS; PERIODONTAL DISEASE; PERIODONTITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STEM CELL; TOOTH PULP;

ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MACROPHAGE COLONY-STIMULATING FACTOR; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; RANK LIGAND; RECEPTORS, IMMUNOLOGIC; TRANSCRIPTION FACTOR AP-1;

EID: 84883565582     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2013.822766     Document Type: Article

References (410)

1. Abu-Amer Y. (2001). IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kB. J Clin Invest, 107, 1375-85
2. Abu-Amer Y, Ross F, Edwards J, Teitelbaum S. (1997). Lipopolysaccharide- stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest, 100, 1557-65
3. Adamopoulos IE, Chao CC, Geissler R, et al. (2010). Interleukin-17A upregulates receptor activator of NF-kB on osteoclast precursors. Arthritis Res Ther, 12, R29
4. Adamopoulos IE, Tessmer M, Chao CC, et al. (2011). IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol, 187, 951-9
5. Agrawal M, Arora S, Li J, et al. (2011). Bone, inflammation, and inflammatory bowel disease. Curr Osteoporos Rep, 9, 251-7
6. Aguila H, Mun S, Kalinowski J, et al. (2012). Osteoblast-specific overexpression of human interleukin-7 rescues the bone mass phenotype of interleukin-7-deficient female mice. J Bone Miner Res, 27, 1030-42
7. Ahlen J, Andersson S, Mukohyama H, et al. (2002). Characterization of the boneresorptive effect of interleukin-11 in cultured mouse calvarial bones. Bone, 31, 242-51
8. Allan E, Hilton D, Brown M, et al. (1990). Osteoblasts display receptors for and responses to leukemia-inhibitory factor. J Cell Physiol, 145, 110-9
9. Alten R, Gram H, Joosten L, et al. (2008). The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proofof- concept study in patients with rheumatoid arthritis. Arthritis Res Ther, 10, R67
10. Arend W, Palmer G, Gabay C. (2008). IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev, 223, 20-38
11. Aya K, Alhawagri M, Hagen-Stapleton A, et al. (2005). NF-(k)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest, 115, 1848-54
12. Baker PJ, Dixon M, Evans RT, et al. (1999). CD4() T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infect Immun, 67, 2804-9
13. Balavoine JF, Derochemonteix B, Williamson K, et al. (1986). Prostaglandin-E2 and Collagenase Production by Fibroblasts and Synovial-Cells Is Regulated by Urine-Derived Human Interleukin-1 and Inhibitor(S). J Clin Invest, 78, 1120-4
14. Banchereau J, Pascual V, O'Garra A. (2012). From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines. Nat Immunol, 13, 925-31
15. Banchereau J, Steinman RM. (1998). Dendritic cells and the control of immunity. Nature, 392, 245-52
16. Barrow AD, Raynal N, Andersen TL, et al. (2011). OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice. J Clin Invest, 121, 3505-16
17. Baud'huin M, Renault R, Charrier C, et al. (2010). Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J pathol, 221, 77-86
18. Bazan J. (1990). Haemopoietic receptors and helical cytokines. Immunology today, 11, 350-4
19. Bellido T, Stahl N, Farruggella T, et al. (1996). Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. J Clin Invest, 97, 431-7
20. Bendixen AC, Shevde NK, Dienger KM, et al. (2001). IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA, 98, 2443-8
21. Bendre M, Margulies A, Walser B, et al. (2005). Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kB ligand pathway. Cancer Res, 65, 11001-9
22. Bendre M, Montague D, Peery T, et al. (2003). Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone, 33, 28-37
23. Bertolini D, Nedwin G, Bringman T, et al. (1986). Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature, 319, 516-8
24. Binder N, Puchner A, Niederreiter B, et al. (2013). Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum, 65, 608-17
25. Bluml S, Binder N, Niederreiter B, et al. (2010). Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum, 62, 1608-19
26. Bonar S, Brydges S, Mueller J, et al. (2012). Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One, 7, e35979
27. Borden EC, Sen GC, Uze G, et al. (2007). Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov, 6, 975-90
28. Boyce BF. (2013). Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res, 28, 711-22
29. Boyce B, Aufdemorte T, Garrett I, et al. (1989). Effects of interleukin-1 on bone turnover in normal mice. Endocrinology, 125, 1142-50
30. Boyce BF, Yao Z, Xing L. (2010). Functions of nuclear factor kB in bone. Ann N Y Acad Sci, 1192, 367-75
31. Bozec A, Bakiri L, Hoebertz A, et al. (2008). Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature, 454, 221-5
32. Braun T, Schett G. (2012). Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep, 10, 101-8
33. Braun T, Zwerina J. (2011). Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis. Arthritis Res Ther, 13, 235
34. Bravo J, Heath JK. (2000). Receptor recognition by gp130 cytokines. EMBO J, 19, 2399-411
35. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. (1998). Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum, 41, 2196-204
36. Bucay N, Sarosi I, Dunstan CR, et al. (1998). osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 12, 1260-8
37. Burnham JM. (2012). Inflammatory diseases and bone health in children. Curr Opin Rheumatol, 24, 548-53
38. Cabal-Hierro L, Lazo P. (2012). Signal transduction by tumor necrosis factor receptors. Cellular signalling, 24, 1297-305
39. Cagnard N, Letourneur F, Essabbani A, et al. (2005). Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. European cytokine network, 16, 289-92
40. Cao Y, Doodes P, Glant T, Finnegan A. (2008). IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. J Immunol, 180, 922-30
41. Carriere V, Roussel L, Ortega N, et al. (2007). IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA, 104, 282-7
42. Cayrol C, Girard J-P. (2009). The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA, 106, 9021-6
43. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al. (2004). Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med, 10, 858-64
44. Chabaud M, Fossiez F, Taupin JL, Miossec P. (1998). Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J Immunol, 161, 409-14
45. Chan AS, Jensen KK, Skokos D, et al. (2009). Id1 represses osteoclastdependent transcription and affects bone formation and hematopoiesis. PLoS One, 4, e7955
46. Cheleuitte D, Mizuno S, Glowacki J. (1998). In vitro secretion of cytokines by human bone marrow: Effects of age and estrogen status. J Clin Endocrinol Metab, 83, 2043-51
47. Chen Z, Buki K, Vaaraniemi J, et al. (2011). The critical role of IL-34 in osteoclastogenesis. PLoS One, 6, e18689
48. Cheng J, Liu J, Shi Z, et al. (2011). Interleukin-4 inhibits RANKL-induced NFATc1 expression via STAT6: A novel mechanism mediating its blockade of osteoclastogenesis. J Cell Biochem, 112, 3385-92
49. Chen L, Wei XQ, Evans B, et al. (2008). IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kB (RANK) expression in myeloid precursor cells. Eur J Immunol, 38, 2845-54
50. The Role of Cytokines in Inflammatory Bone Loss 605 Chiaramonte MG, Mentink-Kane M, Jacobson BA, et al. (2003). Regulation and function of the interleukin 13 receptor alpha 2 during a T helper cell type 2-dominant immune response. J Exp Med, 197, 687-701
51. Chihara T, Suzu S, Hassan R, et al. (2010). IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ, 17, 1917-27
52. Cielinski MJ, Marks Jr SC. (1995). Bone metabolism in the osteopetrotic rat mutation microphthalmia blanc. Bone, 16, 567-74
53. Clohisy JC, Roy BC, Biondo C, et al. (2003). Direct inhibition of NF-k B blocks bone erosion associated with inflammatory arthritis. J Immunol, 171, 5547-53
54. Clohisy JC, Yamanaka Y, Faccio R, Abu-Amer Y. (2006). Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. J Orthop Res, 24, 1358-65
55. Cobelli N, Scharf B, Crisi GM, et al. (2011). Mediators of the inflammatory response to joint replacement devices. Nat Rev Rheumatol, 7, 600-8
56. Cohen S, Hurd E, Cush J, et al. (2002). Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum, 46, 614-24
57. Conaway HH, Persson E, Halen M, et al. (2009). Retinoids inhibit differentiation of hematopoietic osteoclast progenitors. FASEB J, 23, 3526-38
58. Cornish J, Callon K, King A, et al. (1993). The effect of leukemia inhibitory factor on bone in vivo. Endocrinology, 132, 1359-66
59. Crockett JC, Mellis DJ, Scott DI, Helfrich MH. (2011). New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: Focus on the RANK/RANKL axis. Osteoporos Int, 22, 1-20
60. Croft M, Duan W, Choi H, et al. (2012). TNF superfamily in inflammatory disease: Translating basic insights. Trends in immunology, 33, 144-52
61. Cundy T, Reid IR. (2012). Paget's disease of bone. Clin Biochem, 45, 43-8
62. Cush J, Splawski J, Thomas R, et al. (1995). Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum, 38, 96-104
63. D'Andrea A, Yoshimura A, Youssoufian H, et al. (1991). The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growthregulatory domains. Mol Cell Biol, 11, 1980-7
64. Dai S, Hirayama T, Abbas S, Abu-Amer Y. (2004a). The IkB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem, 279, 37219-22
65. Dai SM, Nishioka K, Yudoh K. (2004b). Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: Comparison with IL1 beta and tumour necrosis factor alpha. Ann Rheum Dis, 63, 1379-86
66. Dai XM, Ryan GR, Hapel AJ, et al. (2002). Targeted disruption of the mouse colonystimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood, 99, 111-20
67. De Benedetti F,Massa M, Pignatti P, et al. (1995). Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J Rheumatol, 22, 1581-5
68. De Benedetti F, Rucci N, Del Fattore A, et al. (2006). Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum, 54, 3551-63
69. Derouet D, Rousseau F, Alfonsi F, et al. (2004). Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc Natl Acad Sci USA, 101, 4827-32
70. DeSelm CJ, Takahata Y, Warren J, et al. (2012). IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner. J Cell Biochem, 113, 2895-902
71. Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T. (1985). Purification and partial sequence of human osteoclast-activating factor: Identity with interleukin 1 beta. J Immunol, 135, 2562-8
72. Dhimolea E. (2010). Canakinumab. mAbs, 2, 3-13
73. Dinarello CA. (1994). The interleukin-1 family: 10 years of discovery. FASEB J, 8, 1314-25
74. Dinarello C, Ikejima T, Warner S, et al. (1987). Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. Journal of immunology (Baltimore, Md. : 1950), 139, 1902-10
75. Djaafar S, Pierroz D, Chicheportiche R, et al. (2010). Inhibition of T cell-dependent and RANKL-dependent osteoclastogenic processes associated with high levels of bone mass in interleukin-15 receptor-deficient mice. Arthritis Rheum, 62, 3300-10
76. Dougall WC, Glaccum M, Charrier K, et al. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev, 13, 2412-24
77. Dubois S, Mariner J, Waldmann T, Tagaya Y. (2002). IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity, 17, 537-47
78. Elson GCA, Lelièvre E, Guillet C, et al. (2000). CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex. Nature neuroscience, 3, 867-72
79. Eskan MA, Jotwani R, Abe T, et al. (2012). The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol, 13, 465-73
80. Evans K, Fox S. (2007). Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC cell biology, 8, 4
81. Fan X, Biskobing D, Fan D, et al. (1997). Macrophage colony stimulating factor downregulates MCSF-receptor expression and entry of progenitors into the osteoclast lineage. J Bone Miner Res, 12, 1387-95
82. Fichtner-Feigl S, Strober W, Kawakami K, et al. (2006). IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med, 12, 99-106
83. Finnegan A, Kaplan C, Cao Y, et al. (2003). Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Ther, 5, R18-R24
84. Fox SW, Chambers TJ. (2000). Interferon-gamma directly inhibits TRANCE-induced osteoclastogenesis. Biochem Biophys Res Commun, 276, 868-72
85. Fransson C, Tomasi C, Pikner SS, et al. (2010). Severity and pattern of peri-implantitisassociated bone loss. J Clin Periodontol, 37, 442-8
86. Franzoso G, Carlson L, Xing L, et al. (1997). Requirement for NF-kB in osteoclast and B-cell development. Genes Dev, 11, 3482-96
87. Fujii T, Kitaura H, Kimura K, et al. (2012). IL-4 inhibits TNF-alpha-mediated osteoclast formation by inhibition of RANKL expression in TNF-alpha-activated stromal cells and direct inhibition of TNF-alpha-activated osteoclast precursors via a T-cellindependent mechanism in vivo. Bone, 51, 771-80
88. Fukao T, Matsuda S, Koyasu S. (2000). Synergistic effects of IL-4 and IL-18 on IL-12- dependent IFN-gamma production by dendritic cells. J Immunol, 164, 64-71
89. Furukawa M, Takaishi H, Takito J, et al. (2009). IL-27 abrogates receptor activator of NF-k B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. J Immunol, 183, 2397-406
90. Gabay C, McInnes I. (2009). The biological and clinical importance of the 'new generation' cytokines in rheumatic diseases. Arthritis Res Ther, 11, 230
91. Gabet Y, Baniwal SK, Leclerc N, et al. (2010). Krox20/EGR2 deficiency accelerates cell growth and differentiation in the monocytic lineage and decreases bone mass. Blood, 116, 3964-71
92. Gao Y, Grassi F, Ryan MR, et al. (2007). IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest, 117, 122-32
93. Garbers C, Hermanns HM, Schaper F, et al. (2012). Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev, 23, 85-97
94. Garceau V, Smith J, Paton I, et al. (2010). Pivotal Advance: Avian colony-stimulating factor 1 (CSF-1), interleukin-34 (IL-34), and CSF-1 receptor genes and gene products. J Leukoc Biol, 87, 753-64
95. The Role of Cytokines in Inflammatory Bone Loss 607 Gearing D, Comeau M, Friend D, et al. (1992). The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science, 255, 1434-7
96. Gendron S, Boisvert M, Chetoui N, Aoudjit F. (2008). Alpha1beta1 integrin and interleukin-7 receptor up-regulate the expression of RANKL in human T cells and enhance their osteoclastogenic function. Immunology, 125, 359-69
97. Ghayur T, Banerjee S, Hugunin M, et al. (1997). Caspase-1 processes IFN-gammainducing factor and regulates LPS-induced IFN-gamma production. Nature, 386, 619-23
98. Girasole G, Passeri G, Jilka R, Manolagas S. (1994). Interleukin-11: A new cytokine critical for osteoclast development. J Clin Invest, 93, 1516-24
99. Goldbach-Mansky R, Shroff S, Wilson M, et al. (2008). A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum, 58, 2432-42
100. Goodwin D, Cummins S, Sautkina E, et al. (2013). The role and status of evidence and innovation in the healthy towns programme in England: A qualitative stakeholder interview study. J Epidemiol Community Health, 67, 106-12
101. Gowen M, Mundy GR. (1986). Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J Immunol, 136, 2478-82
102. Gracie J, Forsey R, Chan W, et al. (1999). A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest, 104, 1393-401
103. Gracie J, Robertson S, McInnes I. (2003). Interleukin-18. J Leukoc Biol, 73, 213-24
104. Grassi F, Cristino S, Toneguzzi S, et al. (2004). CXCL12 chemokine up-regulates bone resorption and MMP-9 release by human osteoclasts: CXCL12 levels are increased in synovial and bone tissue of rheumatoid arthritis patients. J Cell Physiol, 199, 244-51
105. Greenfield E, Gornik S, Horowitz M, et al. (1993). Regulation of cytokine expression in osteoblasts by parathyroid hormone: Rapid stimulation of interleukin-6 and leukemia inhibitory factor mRNA. J Bone Miner Res, 8, 1163-71
106. Greenfield EM, Shaw SM, Gornik SA, Banks MA. (1995). Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest, 96, 1238-44
107. Grey A, Mitnick M-A, Masiukiewicz U, et al. (1999). A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology, 140, 4683-90
108. Guerrini MM, Sobacchi C, Cassani B, et al. (2008). Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet, 83, 64-76
109. Harrington LE, Hatton RD, Mangan PR, et al. (2005). Interleukin 17-producing CD4 effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6, 1123-32
110. Hartgring S, Willis C, Alcorn D, et al. (2010). Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum, 62, 2716-25
111. Hartgring S, Willis C, Bijlsma J, et al. (2012). Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res Ther, 14, R137
112. Hattersley G, Dorey E, Horton M, Chambers T. (1988). Human macrophage colonystimulating factor inhibits bone resorption by osteoclasts disaggregated from rat bone. J Cell Physiol, 137, 199-203
113. Hausmann E, Luderitz O, Knox K, Weinfeld N. (1975). Structural requirements for bone resorption by endotoxin and lipoteichoic acid. J Dent Res 54 Spec No, B, B94-9
114. Hausmann E, Raisz LG, Miller WA. (1970). Endotoxin: Stimulation of bone resorption in tissue culture. Science, 168, 862-4
115. Hawlisch H, Belkaid Y, Baelder R, et al. (2005). C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity, 22, 415-26
116. Hayashi M, Rho M-C, Enomoto A, et al. (2002). Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci USA, 99, 14728-33
117. Heinhuis B, Koenders M, van den BergW, et al. (2012b). Interleukin 32 (IL-32) contains a typical a-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1. J Biol Chem, 287, 5733-43
118. Heinhuis B, Netea M, van den Berg W, et al. (2012a). Interleukin-32: A predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine, 60, 321-7
119. Henningsson L, Jirholt P, Bogesta° l Y, et al. (2012). Interleukin 15 mediates joint destruction in Staphylococcus aureus arthritis. The Journal of infectious diseases, 206, 687-96
120. Henriksen K, Bollerslev J, Everts V, Karsdal MA. (2011). Osteoclast activity and subtypes as a function of physiology and pathology-implications for future treatments of osteoporosis. Endocr Rev, 32, 31-63
121. Henschler R, Mantovani L, Oster W, et al. (1990). Interleukin-4 regulates mRNA accumulation of macrophage-colony stimulating factor by fibroblasts: Synergism with interleukin-1 beta. Br J Haematol, 76, 7-11
122. Hodge JM, Collier FM, Pavlos NJ, et al. (2011). M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts. PLoS One, 6, e21462
123. Hofbauer L, Lacey D, Dunstan C, et al. (1999). Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone, 25, 255-9
124. Hoffman H, Throne M, Amar N, et al. (2008). Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum, 58, 2443-52
125. Hofmann S, Rösen-Wolff A, Tsokos G, Hedrich C. (2012). Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clinical immunology (Orlando, Fla.), 143, 116-27
126. Hong M, Williams H, Jin C, Pike J. (2000). The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine- phosphorylated proteins. J Bone Miner Res, 15, 911-8
127. Horai R, Saijo S, Tanioka H, et al. (2000). Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonistdeficient mice. J Exp Med, 191, 313-20
128. Horton JE, Raisz LG, Simmons HA, et al. (1972). Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes. Science, 177, 793-5
129. Horwood N, Elliott J, Martin T, Gillespie M. (1998a). Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology, 139, 4743-6
130. Horwood N, Elliott J, Martin T, Gillespie M. (2001). IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. Journal of immunology (Baltimore, Md.: 1950), 166, 4915-21
131. Horwood NJ, Udagawa N, Elliott J, et al. (1998b). Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest, 101, 595-603
132. Hsu YH, Chang MS. (2010). Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis. Arthritis Rheum, 62, 3311-21
133. Hsu YH, Chen WY, Chan CH, et al. (2011). Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med, 208, 1849-61
134. Hsu YH, Li HH, Hsieh MY, et al. (2006). Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum, 54, 2722-33
135. The Role of Cytokines in Inflammatory Bone Loss 609 Hu R, Sharma SM, Bronisz A, et al. (2007). Eos, MITF, and PU.1 recruit corepressors to osteoclast-specific genes in committed myeloid progenitors. Mol Cell Biol, 27, 4018-27
136. Hu Y, Xiong H, Peng B. (2013). Expression of a cytokine, interleukin-23, in experimental periapical lesions. Int Endod J (Epub ahead of print
137. Hume DA, MacDonald KP. (2012). Therapeutic applications of macrophage colonystimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood, 119, 1810-20
138. Hunter C, Kastelein R. (2012). Interleukin-27: Balancing protective and pathological immunity. Immunity, 37, 960-9
139. Hwang SJ, Choi B, Kang SS, et al. (2012). Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther, 14, R14
140. Ichihara M, Hara T, Kim H, et al. (1997). Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood, 90, 165-73
141. Ikeuchi H, Kuroiwa T, Hiramatsu N, et al. (2005). Expression of interleukin-22 in rheumatoid arthritis: Potential role as a proinflammatory cytokine. Arthritis Rheum, 52, 1037-46
142. Iotsova V, Caamano J, Loy J, et al. (1997). Osteopetrosis in mice lacking NF-kB1 and NF-kB2. Nat Med, 3, 1285-9
143. Ishii M, Egen JG, Klauschen F, et al. (2009). Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature, 458, 524-8
144. Ishii M, Kikuta J, Shimazu Y, et al. (2010). Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med, 207, 2793-8
145. Ishimi Y, Miyaura C, Jin CH, et al. (1990). IL-6 is produced by osteoblasts and induces bone resorption. J Immunol, 145, 3297-303
146. Iwakura Y, Ishigame H, Saijo S, Nakae S. (2011). Functional specialization of interleukin-17 family members. Immunity, 34, 149-62
147. Jazayeri JA, Carroll GJ, Vernallis AB. (2010). Interleukin-6 subfamily cytokines and rheumatoid arthritis: Role of antagonists. Int Immunopharmacol, 10, 1-8
148. Ji JD, Park-Min KH, Shen Z, et al. (2009). Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol, 183, 7223-33
149. Jilka RL, Hamilton JW. (1984). Inhibition of parathormone-stimulated bone resorption by type I interferon. Biochem Biophys Res Commun, 120, 553-8
150. Jilka RL, Hangoc G, Girasole G, et al. (1992). Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science, 257, 88-91
151. Jimi E, Shuto T, Koga T. (1995). Macrophage colony-stimulating factor and interleukin- 1 alpha maintain the survival of osteoclast-like cells. Endocrinology, 136, 808-11
152. Johansson AC, Hansson A, Nandakumar K, et al. (2001). IL-10-deficient B10.Q mice develop more severe collagen-induced arthritis, but are protected from arthritis induced with anti-type II collagen antibodies. J Immunol, 167, 3505-12
153. Jones G, Sebba A, Gu J, et al. (2010). Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis, 69, 88-96
154. Joosten L, Heinhuis B, Netea M, Dinarello C. (2013). Novel insights into the biology of interleukin-32. CMLS
155. Joosten LA, Helsen MM, van De Loo FA, van den Berg WB. (1996). Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum, 39, 797-809
156. Joosten L, Netea M, Kim S-H, et al. (2006). IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA, 103, 3298-303
157. Joosten L, van De Loo F, Lubberts E, et al. (2000). An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis. J Immunol, 165, 6553-8
158. Ju JH, Cho ML, Moon YM, et al. (2008). IL-23 induces receptor activator of NF-kB ligand expression on CD4 T cells and promotes osteoclastogenesis in an autoimmune arthritis model. J Immunol, 181, 1507-18
159. Jules J, Zhang P, Ashley J, et al. (2012). Molecular basis of requirement of receptor activator of nuclear factor kB signaling for interleukin 1-mediated osteoclastogenesis. J Biol Chem, 287, 15728-38
160. Kalliolias G, Zhao B, Triantafyllopoulou A, et al. (2010). Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum, 62, 402-13
161. Kamel Mohamed SG, Sugiyama E, Shinoda K, et al. (2005). Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: A possible mechanism for downregulation of osteoclastogenesis. Biochem Biophys Res Commun, 329, 839-45
162. Kamiya S, Nakamura C, Fukawa T, et al. (2007). Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: Inhibitory effects on osteoclast differentiation. J Bone Miner Metab, 25, 277-85
163. Kamiya S, Okumura M, Chiba Y, et al. (2011). IL-27 suppresses RANKL expression in CD4 T cells in part through STAT3. Immunol Lett, 138, 47-53
164. Kamolmatyakul S, Chen W, Li YP. (2001). Interferon-gamma down-regulates gene expression of cathepsin K in osteoclasts and inhibits osteoclast formation. J Dent Res, 80, 351-5
165. Kasono K, Sato K, Sato Y, et al. (1993). Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture. Bone Miner, 21, 179-88
166. Kato Z, Jee J, Shikano H, et al. (2003). The structure and binding mode of interleukin- 18. Nature structural biology, 10, 966-71
167. Kawase Y, Hoshino T, Yokota K, et al. (2003). Bone malformations in interleukin-18 transgenic mice. J Bone Miner Res, 18, 975-83
168. Keffer J, Probert L, Cazlaris H, et al. (1991). Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. The EMBO journal, 10, 4025-31
169. Keller J, Catala-Lehnen P, Wintges K, et al. (2012). Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun, 417, 217-22
170. Key Jr LL, Rodriguiz RM, Willi SM, et al. (1995). Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med, 332, 1594-9
171. Kikuta J, Ishii M. (2013). Osteoclast migration, differentiation and function: Novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford), 52, 226-34
172. Kikuta J, Iwai K, Saeki Y, Ishii M. (2011). S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Rheumatol Int, 31, 967-9
173. Kim K, Kim JH, Lee J, et al. (2007). MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood, 109, 3253-9
174. Kim KW, Kim HR, Park JY, et al. (2012). Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum, 64, 1015-23
175. Kim YG, Lee CK, Oh J, et al. (2010). Effect of interleukin-32gamma on differentiation of osteoclasts from CD14 monocytes. Arthritis Rheum, 62, 515-23
176. Kimble R, Vannice J, Bloedow D, et al. (1994). Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest, 93, 1959-67
177. Kitami S, Tanaka H, Kawato T, et al. (2010). IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells. Biochimie, 92, 398-404
178. Kitamura H, Kawata H, Takahashi F, et al. (1995). Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. Am J Pathol, 147, 1682-92
179. Kitaura H, Nagata N, Fujimura Y, et al. (2002). Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: Apoptosis mediated by Fas/Fas ligand interaction. J Immunol, 169, 4732-8
180. Kitaura H, Tatamiya M, Nagata N, et al. (2006). IL-18 induces apoptosis of adherent bone marrow cells in TNF-alpha mediated osteoclast formation in synergy with IL-12. Immunol Lett, 107, 22-31
181. Kitaura H, Zhou P, Kim HJ, et al. (2005). M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest, 115, 3418-27
182. Kobayashi M, Fitz L, Ryan M, et al. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med, 170, 827-45
183. Kobayashi K, Takahashi N, Jimi E, et al. (2000). Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med, 191, 275-86
184. Kobayashi Y, Yamamoto K, Saido T, et al. (1990). Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci USA, 87, 5548-52
185. Koga T, Inui M, Inoue K, et al. (2004). Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature, 428, 758-63
186. Kohara H, Kitaura H, Fujimura Y, et al. (2011). IFN-gamma directly inhibits TNFalpha- induced osteoclastogenesis in vitro and in vivo and induces apoptosis mediated by Fas/Fas ligand interactions. Immunol Lett, 137, 53-61
187. Kong YY, Yoshida H, Sarosi I, et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397, 315-23
188. Kotake S, Sato K, Kim KJ, et al. (1996). Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res, 11, 88-95
189. Kotake S, Udagawa N, Takahashi N, et al. (1999). IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest, 103, 1345-52
190. Kotenko SV. (2011). IFN-lambdas. Curr Opin Immunol, 23, 583-90
191. Kudo O, Sabokbar A, Pocock A, et al. (2003). Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone, 32, 1-7
192. Kuestner RE, Taft DW, Haran A, et al. (2007). Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. Journal of Immunology, 179, 5462-73
193. Kumar P, Rajasekaran K, Palmer J, et al. (2013). IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. Journal of Cancer, 4, 57-65
194. Kurihara N, Roodman GD. (1990). Interferons-alpha and -gamma inhibit interleukin-1 beta-stimulated osteoclast-like cell formation in long-term human marrow cultures. J Interferon Res, 10, 541-7
195. Kwok SK, Cho ML, Park MK, et al. (2012). Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum, 64, 740-51
196. Lacey DL, Erdmann JM, Teitelbaum SL, et al. (1995). Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages. Endocrinology, 136, 2367-76
197. Lang D, Knop J, Wesche H, et al. (1998). The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: A novel mechanism of regulation of IL-1 responsiveness. J Immunol, 161, 6871-7
198. Langrish CL, Chen Y, Blumenschein WM, et al. (2005). IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med, 201, 233-40
199. Lauwerys BR, Renauld JC, Houssiau FA. (1999). Synergistic proliferation and activation of natural killer cells by interleukin 12 and interleukin 18. Cytokine, 11, 822-30
200. Lee JH, Cho ML, Kim JI, et al. (2009). Interleukin 17 (IL-17) increases the expression of Toll-like receptor-2, 4, and 9 by increasing IL-1beta and IL-6 production in autoimmune arthritis. J Rheumatol, 36, 684-92
201. Lee B, Kim TH, Jun JB, et al. (2010). Direct inhibition of human RANK osteoclast precursors identifies a homeostatic function of IL-1beta. J Immunol, 185, 5926-34
202. Lee SK, Kalinowski J, Jacquin C, et al. (2006). Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res, 21, 695-702
203. Lee SK, Kalinowski J, Jastrzebski S, et al. (2003). Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology, 144, 3524-31
204. Lee J, Kim K, Kim JH, et al. (2006). Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood, 107, 2686-93
205. Lee J, Lee J, Park MK, et al. (2013). Interferon Gamma Suppresses Collagen-Induced Arthritis by Regulation of Th17 through the Induction of Indoleamine-2,3- Deoxygenase. PLoS One, 8, e60900
206. Lerner UH, Ohlin A. (1993). Tumor necrosis factors alpha and beta can stimulate bone resorption in cultured mouse calvariae by a prostaglandin- independent mechanism. J Bone Miner Res, 8, 147-55
207. Leung B, McInnes I, Esfandiari E, et al. (2000). Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J Immunol, 164, 6495-502
208. Li J, Sarosi I, Yan XQ, et al. (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA, 97, 1566-71
209. Li X, Kim KW, Cho ML, et al. (2010). IL-23 induces receptor activator of NF-kB ligand expression in fibroblast-like synoviocytes via STAT3 and NF-kB signal pathways. Immunol Lett, 127, 100-7
210. Li Y, Messina C, Bendaoud M, et al. (2010). Adaptive immune response in osteoclastic bone resorption induced by orally administered Aggregatibacter actinomycetemcomitans in a rat model of periodontal disease. Molecular oral microbiology, 25, 275-92
211. Liang S, Krauss JL, Domon H, et al. (2011). The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss. J Immunol, 186, 869-77
212. Lin H, Lee E, Hestir K, et al. (2008). Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science, 320, 807-11
213. Liu YC, Lerner UH, Teng YT. (2010). Cytokine responses against periodontal infection: Protective and destructive roles. Periodontol (2000), 52, 163-206
214. Lorenzo J, Sousa S, Alander C, et al. (1987). Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum to interleukin 1. Endocrinology, 121, 1164-70
215. Lorenzo J, Sousa S, Leahy C. (1990). Leukemia inhibitory factor (LIF) inhibits basal bone resorption in fetal rat long bone cultures. Cytokine, 2, 266-71
216. Lubbers J, Brink M, van De Stadt LA, et al. (2013). The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. Ann Rheum Dis, 72, 776-80
217. Lubberts E, Joosten LA, Chabaud M, et al. (2000). IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest, 105, 1697-710
218. Ma T, Miyanishi K, Suen A, et al. (2004). Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-alpha. Cytokine, 26, 138-44
219. Mabilleau G, Sabokbar A. (2009). Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS One, 4, e4173
220. Maini RN, Taylor PC, Szechinski J, et al. (2006). Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum, 54, 2817-29
221. The Malinowsky D, Lundkvist J, Layé S, Bartfai T. (1998). Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett, 429, 299-302
222. Mangashetti LS, Khapli SM, Wani MR. (2005). IL-4 inhibits bone-resorbing activity of mature osteoclasts by affecting NF-kB and Ca2 signaling. J Immunol, 175, 917-25
223. Mann GN, Jacobs TW, Buchinsky FJ, et al. (1994). Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology, 135, 1077-83
224. Martin TJ, Seeman E. (2008). Bone remodelling: Its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab, 22, 701-22
225. Micallef MJ, Ohtsuki T, Kohno K, et al. (1996). Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-gamma production. Eur J Immunol, 26, 1647-51
226. Miller A. (2011). Role of IL-33 in inflammation and disease. J Inflammation, 8, 22
227. Miossec P, Chomarat P, Dechanet J, et al. (1994). Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum, 37, 1715-22
228. Miranda-Carú s M-E, Benito-Miguel M, Balsa A, et al. (2006). Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum, 54, 1151-64
229. Miura M, Zhu H, Rotello R, et al. (1993). Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell, 75, 653-60
230. Miyauchi Y, Ninomiya K, Miyamoto H, et al. (2010). The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis. J Exp Med, 207, 751-62
231. Miyaura C, Onoe Y, Inada M, et al. (1997). Increased B-lymphopoiesis by interleukin 7 induces bone loss in mice with intact ovarian function: Similarity to estrogen deficiency. Proc Natl Acad Sci USA, 94, 9360-5
232. Mócsai A, Humphrey M, Van Ziffle J, et al. (2004). The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA, 101, 6158-63
233. Mohamed S, Sugiyama E, Shinoda K, et al. (2007). Interleukin-10 inhibits RANKLmediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone, 41, 592-602
234. Monroe KM, McWhirter SM, Vance RE. (2010). Induction of type I interferons by bacteria. Cell Microbiol, 12, 881-90
235. Moon YM, Yoon BY, Her YM, et al. (2012). IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther, 14, R246
236. Moreno JL, Kaczmarek M, Keegan AD, Tondravi M. (2003). IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: Irreversible inhibition of the differentiation program activated by RANKL. Blood, 102, 1078-86
237. Morita Y, Kitaura H, Yoshimatsu M, et al. (2010). IL-18 inhibits TNF-alpha-induced osteoclastogenesis possibly via a T cell-independent mechanism in synergy with IL-12 in vivo. Calcif Tissue Int, 86, 242-8
238. Müller J, Waldmann T, Kruhlak M, Dubois S. (2012). Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15Ra in human monocytes and dendritic cells. J Biol Chem, 287, 40328-38
239. Munder M, Mallo M, Eichmann K, Modolell M. (1998). Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med, 187, 2103-8
240. Murugaiyan G, Saha B. (2013). IL-27 in tumor immunity and immunotherapy. Trends in molecular medicine, 19, 108-16
241. Nagasaki K, Yamaguchi K, Watanabe K, et al. (1991). Interleukin-4 blocks parathyroid hormone-related protein-induced hypercalcemia in vivo. Biochem Biophys Res Commun, 178, 694-8
242. Nagata N, Kitaura H, Yoshida N, Nakayama K. (2003). Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: Involvement of IFN-gamma possibly induced from non-T cell population. Bone, 33, 721-32
243. Nakamichi Y, Mizoguchi T, Arai A, et al. (2012). Spleen serves as a reservoir of osteoclast precursors through vitamin D-induced IL-34 expression in osteopetrotic op/op mice. Proc Natl Acad Sci USA, 109, 10006-11
244. Nakano Y, Watanabe K, Morimoto I, et al. (1994). Interleukin-4 inhibits spontaneous and parathyroid hormone-related protein-stimulated osteoclast formation in mice. J Bone Miner Res, 9, 1533-9
245. Nakashima T, Hayashi M, Takayanagi H. (2012). New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab, 23, 582-90
246. Negishi-Koga T, Takayanagi H. (2009). Ca2-NFATc1 signaling is an essential axis of osteoclast differentiation. Immunol Rev, 231, 241-56
247. Netea M, Nold-Petry C, Nold M, et al. (2009). Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood, 113, 2324-35
248. Niedbala W, Cai B, Wei X, et al. (2008). Interleukin 27 attenuates collagen-induced arthritis. Ann Rheum Dis, 67, 1474-9
249. Nishimoto N, Hashimoto J, Miyasaka N, et al. (2007). Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis, 66, 1162-7
250. Novack DV. (2011). Role of NF-kB in the skeleton. Cell Res, 21, 169-82
251. Novack DV, Yin L, Hagen-Stapleton A, et al. (2003). The IkB function of NF-kB2 p100 controls stimulated osteoclastogenesis. J Exp Med, 198, 771-81
252. Novick D, Kim S, Fantuzzi G, et al. (1999). Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity, 10, 127-36
253. Nuki G, Bresnihan B, Bear MB, McCabe D. (2002). Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 46, 2838-46
254. O'Brien C, Gubrij I, Lin S, et al. (1999). STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem, 274, (1930)1-8
255. Ogata Y, Kukita A, Kukita T, et al. (1999). A novel role of IL-15 in the development of osteoclasts: Inability to replace its activity with IL-2. J Immunol, 162, 2754-60
256. Ohteki T, Fukao T, Suzue K, et al. (1999). Interleukin 12-dependent interferon gamma production by CD8alpha lymphoid dendritic cells. J Exp Med, 189, 1981-6
257. Okamura H, Tsutsi H, Komatsu T, et al. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature, 378, 88-91
258. Oppmann B, Lesley R, Blom B, et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13, 715-25
259. O'Shea J, Gadina M, Schreiber R. (2002). Cytokine signaling in (2002): New surprises in the Jak/Stat pathway. Cell, 109, 31
260. Otero JE, Chen T, Zhang K, Abu-Amer Y. (2012a). Constitutively active canonical NF-kB pathway induces severe bone loss in mice. PLoS One, 7, e38694
261. Otero JE, Dai S, Alhawagri MA, et al. (2010). IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res, 25, 1282-94
262. Otero JE, Dai S, Foglia D, et al. (2008). Defective osteoclastogenesis by IKKbetanull precursors is a result of receptor activator of NF-kB ligand The Role of Cytokines in Inflammatory Bone Loss 615 (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J Biol Chem, 283, 24546-53
263. Otero K, Shinohara M, Zhao H, et al. (2012b). TREM2 and b-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol, 188, 2612-21
264. Owens J, Gallagher A, Chambers T. (1996). IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J Immunol, 157, 936-40
265. Palmer G, Talabot-Ayer D, Lamacchia C, et al. (2009). Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum, 60, 738-49
266. Palmqvist P, Lundberg P, Persson E, et al. (2006). Inhibition of hormone and cytokinestimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin- 13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. J Biol Chem, 281, 2414-29
267. Palmqvist P, Persson E, Conaway HH, Lerner UH. (2002). IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kB ligand, osteoprotegerin, and receptor activator of NF-kB in mouse calvariae. J Immunol, 169, 3353-62
268. Parham C, Chirica M, Timans J, et al. (2002). A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol, 168, 5699-708
269. Park H, Li Z, Yang XO, et al. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6, 1133-41
270. Park JS, Jung Y, Oh HJ, et al. (2012). Interleukin-27 suppresses osteoclastogenesis via induction of interferon-g. Immunology, 137, 326-35
271. Park M, Her YM, Cho M, et al. (2011). IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis. Immunol Lett, 139, 42-51
272. Park YD, Kim YS, Jung YM, et al. (2012). Porphyromonas gingivalis lipopolysaccharide regulates interleukin (IL)-17 and IL-23 expression via SIRT1 modulation in human periodontal ligament cells. Cytokine, 60, 284-93
273. Park-Min KH, Ji JD, Antoniv T, et al. (2009). IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kB signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J Immunol, 183, 2444-55
274. Park-Min KH, Lee EY, Moskowitz NK, et al. (2013). Negative regulation of osteoclast precursor differentiation by CD11b and beta2 integrin-B-cell lymphoma 6 signaling. J Bone Miner Res, 28, 135-49
275. Perkins SL, Kling SJ. (1995). Local concentrations of macrophage colony-stimulating factor mediate osteoclastic differentiation. Am J Physiol, 269, E1024-30
276. Persson S, Mikulowska A, Narula S, et al. (1996). Interleukin-10 suppresses the development of collagen type II-induced arthritis and ameliorates sustained arthritis in rats. Scandinavian journal of immunology, 44, 607-14
277. Pestka S, Krause CD, Walter MR. (2004). Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 202, 8-32
278. Peterlik M, Hoffmann O, Swetly P, et al. (1985). Recombinant gamma-interferon inhibits prostaglandin-mediated and parathyroid hormone-induced bone resorption in cultured neonatal mouse calvaria. FEBS Lett, 185, 287-90
279. Pickens S, Chamberlain N, Volin M, et al. (2011b). Local expression of interleukin-27 ameliorates collagen-induced arthritis. Arthritis Rheum, 63, 2289-98
280. Pickens S, Chamberlain N, Volin M, et al. (2011a). Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum, 63, 2884-93
281. Platanias LC. (2005). Mechanisms of type-I- And type-II-interferon- mediated signalling. Nat Rev Immunol, 5, 375-86
282. Poli V, Balena R, Fattori E, et al. (1994). Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. The EMBO journal, 13, 1189-96
283. Popadiak K, Potempa J, Riesbeck K, Blom AM. (2007). Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. J Immunol, 178, 7242-50
284. Presky D, Yang H, Minetti L, et al. (1996). A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA, 93, 14002-7
285. Puddu P, Fantuzzi L, Borghi P, et al. (1997). IL-12 induces IFN-gamma expression and secretion in mouse peritoneal macrophages. J Immunol, 159, 3490-7
286. Qian Y, Liu C, Hartupee J, et al. (2007). The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol, 8, 247-56
287. Quinn JM, Sims NA, Saleh H, et al. (2008). IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol, 181, 5720-9
288. Ratner M. (2008). IL-1 trap go-ahead. Nature biotechnology, 26, 485
289. Redlich K, Smolen J. (2012). Inflammatory bone loss: Pathogenesis and therapeutic intervention. Nat Rev Drug Discov, 11, 234-50
290. Reid L, Lowe C, Cornish J, et al. (1990). Leukemia inhibitory factor: A novel bone-active cytokine. Endocrinology, 126, 1416-20
291. Riancho JA, Zarrabeitia MT, Gonzalez-Macias J. (1993b). Interleukin-4 modulates osteoclast differentiation and inhibits the formation of resorption pits in mouse osteoclast cultures. Biochem Biophys Res Commun, 196, 678-85
292. Riancho JA, Zarrabeitia MT, Mundy GR, et al. (1993a). Effects of interleukin-4 on the formation of macrophages and osteoclast-like cells. J Bone Miner Res, 8, 1337-44
293. Richards C, Langdon C, Deschamps P, et al. (2000). Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine, 12, 613-21
294. Romas E, Udagawa N, Zhou H, et al. (1996). The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med, 183, 2581-91
295. Ruchatz H, Leung B, Wei X, et al. (1998). Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology. J Immunol, 160, 5654-60
296. Ruocco MG, Maeda S, Park JM, et al. (2005). IkB kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med, 201, 1677-87
297. Ruth J, Park C, Amin M, et al. (2010). Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritis. Arthritis Res Ther, 12, R118
298. Ryan M, Shepherd R, Leavey J, et al. (2005). An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA, 102, 16735-40
299. Sabatini M, Boyce B, Aufdemorte T, et al. (1988). Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci USA, 85, 5235-9
300. Saleh H, Eeles D, Hodge J, et al. (2011). Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology, 152, 1911-22
301. Sarra M, Cupi M, Pallone F, Monteleone G. (2012). Interleukin-21 in immune and allergic diseases. Inflammation & allergy drug targets, 11, 313-9
302. Sasaki H, Okamatsu Y, Kawai T, et al. (2004). The interleukin-10 knockout mouse is highly susceptible to Porphyromonas gingivalis-induced alveolar bone loss. Journal of periodontal research, 39, 432-41
303. Sato K, Fujii Y, Kasono K, et al. (1986). Stimulation of prostaglandin E2 and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones. Biochem Biophys Res Commun, 138, 618-24
304. Sato K, Suematsu A, Okamoto K, et al. (2006). Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med, 203, 2673-82
305. Schett G, Gravallese E. (2012). Bone erosion in rheumatoid arthritis: Mechanisms, diagnosis and treatment. Nat Rev Rheumatol, 8, 656-64
306. Schmitz J, Owyang A, Oldham E, et al. (2005). IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity, 23, 479-90
307. Schroder K, Tschopp J. (2010). The inflammasomes. Cell, 140, 821-32
308. Schulze J, Bickert T, Beil F, et al. (2011). Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res, 26, 704-17
309. Seckinger P, Williamson K, Balavoine J, et al. (1987). A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol, 139, 1541-5
310. Seder RA, Paul WE. (1994). Acquisition of lymphokine-producing phenotype by CD4 T cells. Annu Rev Immunol, 12, 635-73
311. Shalom-Barak T, Quach J, Lotz M. (1998). Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kB. J Biol Chem, 273, 27467-73
312. Shanmugarajan S, Kawanabe N, Koide M, et al. (2009). IL-12 stimulates the osteoclast inhibitory peptide-1 (OIP-1/hSca) gene expression in CD4 T cells. J Cell Biochem, 107, 104-11
313. Shen F, Ruddy MJ, Plamondon P, Gaffen SL. (2005). Cytokines link osteoblasts and inflammation: Microarray analysis of interleukin-17- And TNF-alpha-induced genes in bone cells. J Leukoc Biol, 77, 388-99
314. Shioi A, Teitelbaum SL, Ross FP, et al. (1991). Interleukin 4 inhibits murine osteoclast formation in vitro. J Cell Biochem, 47, 272-7
315. Silva MJ, Kajiya M, AlShwaimi E, et al. (2012). Bacteria-reactive immune response may induce RANKL-expressing T cells in the mouse periapical bone loss lesion. J Endod, 38, 346-50
316. Simonet WS, Lacey DL, Dunstan CR, et al. (1997). Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell, 89, 309-19
317. Sims N. (2009). gp130 signaling in bone cell biology: Multiple roles revealed by analysis of genetically altered mice. Molecular and cellular endocrinology, 310, 30-9
318. Sims NA, Jenkins BJ, Nakamura A, et al. (2005). Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res, 20, 1093-102
319. Sims N, Walker E, Poulton I, et al. (2007). Oncostatin M is an essential stimulus of bone formation and osteoclastogenesis. J. Bone Miner Res, 22, S19
320. Smeets TJ, Dayer JM, Kraan MC, et al. (2000). The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum, 43, 270-4
321. Smith D. (2011). The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol, 89, 383-92
322. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. (2008). Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet, 371, 987-97
323. Sobacchi C, Frattini A, Guerrini MM, et al. (2007). Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet, 39, 960-2
324. Souza PP, Palmqvist P, Lundberg P, et al. (2012). Interleukin-4 and interleukin-13 inhibit the expression of leukemia inhibitory factor and interleukin-11 in fibroblasts. Mol Immunol, 49, 601-10
325. Souza PPC, Brechter AB, Reis RI, et al. (2013). IL-4 and IL-13 inhibit IL-1b and TNF-a induced kinin B1 and B2 receptors through a STAT6-dependent mechanism. Br J Pharmacol, 169, 400-12
326. Stashenko P, Dewhirst F, Peros W, et al. (1987). Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol, 138, 1464-8
327. Stashenko P, Goncalves RB, Lipkin B, et al. (2007). Th1 immune response promotes severe bone resorption caused by Porphyromonas gingivalis. Am J Pathol, 170, 203-13
328. Steel J, Waldmann T, Morris J. (2012). Interleukin-15 biology and its therapeutic implications in cancer. Trends in pharmacological sciences, 33, 35-41
329. Stein NC, Kreutzmann C, Zimmermann SP, et al. (2008). Interleukin-4 and interleukin- 13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J Bone Miner Res, 23, 750-8
330. Stoll S, Jonuleit H, Schmitt E, et al. (1998). Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol, 28, 3231-9
331. Stoll S, Müller G, Kurimoto M, et al. (1997). Production of IL-18 (IFN-gamma-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol, 159, 298-302
332. Taga T, Hibi M, Hirata Y, et al. (1989). Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58, 573-81
333. Tak PP, Hart BA, Kraan MC, et al. (1999). The effects of interferon beta treatment on arthritis. Rheumatology (Oxford), 38, 362-9
334. Takahashi N, Mundy GR, Roodman GD. (1986). Recombinant human interferongamma inhibits formation of human osteoclast-like cells. J Immunol, 137, 3544-9
335. Takayanagi H. (2012). New developments in osteoimmunology. Nat Rev Rheumatol, 8, 684-9
336. Takayanagi H, Iizuka H, Juji T, et al. (2000a). Involvement of receptor activator of nuclear factor kB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum, 43, 259-69
337. Takayanagi H, Kim S, Koga T, et al. (2002a). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell, 3, 889-901
338. Takayanagi H, Kim S, Matsuo K, et al. (2002b). RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature, 416, 744-9
339. Takayanagi H, Kim S, Taniguchi T. (2002c). Signaling crosstalk between RANKL and interferons in osteoclast differentiation. Arthritis Res 4 Suppl, 3, S227-32
340. Takayanagi H, Ogasawara K, Hida S, et al. (2000b). T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature, 408, 600-5
341. Takeshita S, Namba N, Zhao JJ, et al. (2002). SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts. Nat Med, 8, 943-9
342. Tamura T, Udagawa N, Takahashi N, et al. (1993). Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA, 90, 11924-8
343. Tashjian A, Voelkel E, Lazzaro M, et al. (1987). Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology, 120, 2029-36
344. Thomson B, Mundy G, Chambers T. (1987). Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol, 138, 775-9
345. Thunell D, Tymkiw K, Johnson G, et al. (2010). A multiplex immunoassay demonstrates reductions in gingival crevicular fluid cytokines following initial periodontal therapy. J Periodontal Res, 45, 148-52
346. Tokuda H, Kanno Y, Ishisaki A, et al. (2004). Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem, 91, 1053-61
347. Toraldo G, Roggia C, Qian W-P, et al. (2003). IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kB ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA, 100, 125-30
348. Townsend MJ, Fallon PG, Matthews DJ, et al. (2000). T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med, 191, 1069-76
349. Treschow AP, Teige I, Nandakumar KS, et al. (2005). Stromal cells and osteoclasts are responsible for exacerbated collagen-induced arthritis in interferon-beta-deficient mice. Arthritis Rheum, 52, 3739-48
350. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. (1999). Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum, 42, 90-9
351. Trinchieri G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol, 3, 133-46
352. Trinchieri G. (2010). Type I interferon: Friend or foe? J Exp Med, 207, 2053-63
353. Tsukii K, Shima N, Mochizuki S, et al. (1998). Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem Biophys Res Commun, 246, 337-41
354. Tymkiw K, Thunell D, Johnson G, et al. (2011). Influence of smoking on gingival crevicular fluid cytokines in severe chronic periodontitis. J Clinical Periodontol, 38, 219-28
355. Udagawa N, Horwood NJ, Elliott J, et al. (1997). Interleukin-18 (interferon-gammainducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med, 185, 1005-12
356. Udagawa N, Takahashi N, Katagiri T, et al. (1995). Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med, 182, 1461-8
357. Vaira S, Alhawagri M, Anwisye I, et al. (2008b). RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest, 118, 2088-97
358. Vaira S, Johnson T, Hirbe AC, et al. (2008a). RelB is the NF-kB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA, 105, 3897-902
359. Van bezooijen RL, Farih-Sips HC, Papapoulos SE, Lowik CW. (1999). Interleukin-17: A new bone acting cytokine in vitro. J Bone Miner Res, 14, 1513-21
360. Van Bezooijen RL, Papapoulos SE, Lowik CW. (2001). Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: Is there dependency on nuclear factor-kB and receptor activator of nuclear factor kB (RANK)/RANK ligand signaling? Bone, 28, 378-86
361. Van Bezooijen RL, Van Der Wee-Pals L, Papapoulos SE, Lowik CW. (2002). Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann Rheum Dis, 61, 870-6
362. van Roon J, Hartgring S, Wenting-van Wijk M, et al. (2007). Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann Rheum Dis, 66, 664-9
363. van Roon J, Lafeber F. (2008). Role of interleukin-7 in degenerative and inflammatory joint diseases. Arthritis Res Ther, 10, 107
364. van't Hof RJ, Ralston SH. (1997). Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity. J Bone Miner Res, 12, 1797-804
365. Volin M, Koch A. (2011). Interleukin-18: A mediator of inflammation and angiogenesis in rheumatoid arthritis. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 31, 745-51
366. Wada N, Maeda H, Yoshimine Y, Akamine A. (2004). Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kB ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone, 35, 629-35
367. Wagner EF, Eferl R. (2005). Fos/AP-1 proteins in bone and the immune system. Immunol Rev, 208, 126-40
368. Waldmann T. (2006). The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol, 6, 595-601
369. Walker E, McGregor N, Poulton I, et al. (2008). Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res, 23, 2025-32
370. Wang Y, Robledo O, Kinzie E, et al. (2000). Receptor subunit-specific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem, 275, 25273-85
371. Ware C, Horowitz M, Renshaw B, et al. (1995). Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development, 121, 1283-99
372. Watanabe K, Tanaka Y, Morimoto I, et al. (1990). Interleukin-4 as a potent inhibitor of bone resorption. Biochem Biophys Res Commun, 172, 1035-41
373. Weber A, Wasiliew P, Kracht M. (2010). Interleukin-1 (IL-1) pathway. Sci Signal, 3, 1-2
374. Wei S, Kitaura H, Zhou P, et al. (2005). IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest, 115, 282-90
375. Wei S, Nandi S, Chitu V, et al. (2010). Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol, 88, 495-505
376. Wei S, Wang MW, Teitelbaum SL, Ross FP. (2002). Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kB and mitogen-activated protein kinase signaling. J Biol Chem, 277, 6622-30
377. Wei X, Leung B, Arthur H, et al. (2001). Reduced incidence and severity of collageninduced arthritis in mice lacking IL-18. J Immunol, 166, 517-21
378. Weitzmann M, Cenci S, Rifas L, et al. (2000). Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood, 96, 1873-8
379. Weitzmann M, Roggia C, Toraldo G, et al. (2002). Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest, 110, 1643-50
380. Wright JF, Bennett F, Li BL, et al. (2008). The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol, 181, 2799-805
381. Wright LM, Maloney W, Yu X, et al. (2005). Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone, 36, 840-53
382. Xing L, Bushnell TP, Carlson L, et al. (2002). NF-kB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- And cytokine-mediated osteoclastogenesis. J Bone Miner Res, 17, 1200-10
383. Xu S, Cao X. (2010). Interleukin-17 and its expanding biological functions. Cell Mol Immunol, 7, 164-74
384. Xu D, Jiang H-R, Kewin P, et al. (2008). IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA, 105, 10913-8
385. Xu L, Kukita T, Kukita A, et al. (1995). Interleukin-10 selectively inhibits osteoclastogenesis by inhibiting differentiation of osteoclast progenitors into preosteoclast-like cells in rat bone marrow culture system. J Cell Physiol, 165, 624-9
386. Xu Z, Hurchla MA, Deng H, et al. (2009). Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. J Biol Chem, 284, 4658-66
387. Yago T, Nanke Y, Ichikawa N, et al. (2009). IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: A novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem, 108, 947-55
388. Yamada N, Niwa S, Tsujimura T, et al. (2002). Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone, 30, 901-8
389. Yamanaka Y, Abu-Amer W, Foglia D, et al. (2008). NFAT2 is an essential mediator of orthopedic particle-induced osteoclastogenesis. J Orthop Res, 26, 1577-84
390. Yamashita T, Yao Z, Li F, et al. (2007). NF-kB p50 and p52 regulate receptor activator of NF-kB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem, 282, 18245-53
391. Yang C, McCoy K, Davis JL, et al (2010). NIK stabilization in osteoclasts results in osteoporosis and enhanced inflammatory osteolysis. PLoS One, 5, e15383
392. Yang S, Madyastha P, Ries W, Key LL. (2002). Characterization of interferon gamma receptors on osteoclasts: Effect of interferon gamma on osteoclastic superoxide generation. J Cell Biochem, 84, 645-54
393. Yao Z, Xing L, Boyce BF. (2009). NF-kB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest, 119, 3024-34
394. Ying F, Chalise JP, Narendra SC, Magnusson M. (2011). Type I IFN protects against antigen-induced arthritis. Eur J Immunol, 41, 1687-95
395. Yoshida H, Hayashi S, Kunisada T, et al. (1990). The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature, 345, 442-4
396. Yoshimatsu M, Kitaura H, Fujimura Y, et al. (2009). IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone, 45, 1010-6
397. Yoshimatsu M, Kitaura H, Fujimura Y, et al. (2012). Inhibitory effects of IL-12 on experimental tooth movement and root resorption in mice. Arch Oral Biol, 57, 36-43
398. Yoshitake F, Itoh S, Narita H, et al. (2008). Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kB signaling pathways. J Biol Chem, 283, 11535-40
399. Yu X, Huang Y, Collin-Osdoby P, Osdoby P. (2003). Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res, 18, 1404-18
400. Yu JJ, Ruddy MJ, Wong GC, et al. (2007). An essential role for IL-17 in preventing pathogen-initiated bone destruction: Recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood, 109, 3794-802
401. Zhang Q, Guo R, Schwarz EM, et al. (2008). TNF inhibits production of stromal cellderived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood. Arthritis Res Ther, 10, R37
402. Zhang Y, Heulsmann A, Tondravi M, et al. (2001). Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem, 276, 563-8
403. Zhang F, Tanaka H, Kawato T, et al. (2011). Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie, 93, 296-305
404. Zhao B, Grimes SN, Li S, et al. (2012). TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J. J Exp Med, 209, 319-34
405. Zhao B, Ivashkiv LB. (2011). Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Ther, 13, 234
406. Zhao B, Takami M, Yamada A, et al. (2009). Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med, 15, 1066-71
407. Zheng H, Yu X, Collin-Osdoby P, Osdoby P. (2006). RANKL stimulates inducible nitricoxide synthase expression and nitric oxide production in developing osteoclasts. An autocrine negative feedback mechanism triggered by RANKL-induced interferonbeta via NF-kB that restrains osteoclastogenesis and bone resorption. J Biol Chem, 281, 15809-20
408. Zheng T, Zhu Z, Liu W, et al. (2003). Cytokine regulation of IL-13Ralpha2 and IL-13Ralpha1 in vivo and in vitro. J Allergy Clin Immunol, 111, 720-8
409. Zhou P, Kitaura H, Teitelbaum SL, et al. (2006). SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27. J Immunol, 177, 8777-84
410. Zwerina J, Redlich K, Polzer K, et al. (2007). TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA, 104, 11742-7